Dr Kochenderfer speaks with ecancer at the ASH 2017 annual meeting about clinical activity seen with anti-BCMA CAR T-cell therapy in a phase 1 study of people with heavily pre-treated multiple myeloma.
Read the news story or watch the press conference for more information.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
